Pharma intelligence in minutes,
not meetings.
FDA approvals, trials, patents, pipelines — into clear decisions, fast.
Try:
·
·
·
·
·
8,500+ drugs · 148,000+ trials · 1,300+ patent landscapes · Updated weekly.
Start 30-day Pro trial — free →
No credit card required
Questions TheraRadar answers
Tap any question to jump straight to the data.
Recent FDA Approvals
Updated May 30, 2026
Upcoming FDA Decisions
Full calendarBaxdrostat
AstraZeneca PLC
2026-06-15
4d away
Camizestrant
AstraZeneca PLC
2026-06-15
4d away
Nilopki (XS003, nilotinib)
Xspray Pharma AB
2026-06-18
7d away
Latest brief Same Mechanism, Different Trial: How the FDA Rejected Patisiran but Approved Vutrisiran
All briefs → Pro tools
Pre-built analyses. The slow research is already done.
🧬
Competitive heatmaps
90+ interactive grids — indication landscapes (company × mechanism), company portfolios, and MOA platforms. Click any cell to drill into the trials.
⚖️
Compare two companies
Head-to-head comparison of any two company portfolios — pipeline, approvals, and revenue side by side.
🔬
Clinical Trials Explorer
Search and filter 148,000+ trials by drug, sponsor, phase, and condition.
📉
Patent Cliff with revenue arcs
Humira -73%, Revlimid -81%, Stelara -43% — actual SEC revenue declines, not Medicare proxies.
Data sources: FDA Drugs@FDA, ClinicalTrials.gov, Orange Book, SEC EDGAR.
Data updated: Jun 3, 2026